Иммунологические последствия индукции антител к IFN#3[Г]#1 и IL-4 их пептидными фрагментами
Диссертация
Научная новизна. Впервые на основе теоретического анализа рассчитана локализация иммунодоминантных эпитопов молекул IFN-y и IL-4 мыши. Синтезирован один петид, воспроизводящий иммунодоминантный эпитоп IFN-y, и два пептида, соответствующие иммунодоминантным эпитопам IL-4 мыши. Отработаны условия иммунизации, позволившие индуцировать антитела к пептидному фрагментаму 99−113 из IFN-y, и антитела… Читать ещё >
Список литературы
- Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М., «Фармарус Принт». 1998
- Лукина Г. В. Перспективы анти-цитокиновой терапии при ревматоидном артрите. Вестн. Российской Акад. Мед. Наук. 2003. № 7. С.23−27.
- Пыцкий В.И., Адрианова Н. В., Артамасова А. В. Аллергические заболевания. М., «Медицина». 1991, с. 366
- Сергеев П.В., Шимановский H.JI. Рецепторы физиологически активных веществ. М., «Медицина». 1987.
- Хаитов P.M., Игнатьева Г. А., Сидорович И. Г. Иммунология Учебник. М., «Медицина», 2002.
- Шарова Н.И., Литвина М. М., Шевелев С. В., Дзуцев А. Х., Ярилин А. А. Выработка интерферона g и интерлейкина 4 тимоцитами человека in vitro. Цитокины и Воспаление. 2002. № 4. С. 10−15.
- Ярилин А.А., Основы Иммунологии, Москва, «Медицина», 1999
- Ярилин А.А. Интерфероны. Молекулярное многообразие и биологические свойства Биопрепараты. 2006. № 3. С. 2−4.
- Abbas А. К., Lichtman А.Н., Pober J.S. Cellular and molecular immunology. 2nd ed. W. B Saunders Co.Philadelphia. 1994.
- Afeltra A. Treatment of rheumatoid arthritis: new therapeutic approaches with biological agents. Curr Drug Targets Immune Endocr Metabol Disord. 2001 May- 1(1): 45−65.
- Agnello D, Lankford CS, Bream J, Morinobu A, Gadina M, O’Shea JJ, Frucht DM. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol. 2003 May- 23(3): 147−61.
- Allen JE, Maizels RM. Thl-Th2: reliable paradigm or dangerous dogma? Immunol Today. 1997 Aug- 18(8): 387−92.
- Amerio P, Frezzolini A, Feliciani C, Verdolini R, Teofoli P, De Pita O, Puddu P. Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications. Curr Drug Targets Inflamm Allergy. 2003 Mar- 2(1): 81−94.
- Andreakos ET, Foxwell BM, Brennan FM, Maini RN, Feldmann M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev. 2002 Aug-Oct- 13(4−5): 299−313.
- Antonelli G, Currenti M, Turriziani O, Dianzani F. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis. 1991 Apr- 163(4): 882−5.
- Ashkar S, Weber GF, Panoutsakopoulou V. et al. Critical contribution of 0X40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J Exp Med. 2000 Jan 17- 191(2): 375−80.
- Balamuth F, Leitenberg D, Unternaehrer J, Mellman I, Bottomly K. Distinct patterns of membrane microdomain partitioning in Thl and th2 cells. Immunity. 2001 Nov- 15(5): 729−38
- Balsari A, Caruso A. Natural antibodies to IL-2. Biotherapy. 1997- 10(1): 25−8.
- Banchereau J, Briere F, Liu YJ, Rousset F. Molecular control of B lymphocyte growth and differentiation. Stem Cells. 1994 May- 12(3): 278−88.
- Barrera P., Oyen W.J., Boerman O.C. and Van Riel P.L. (2003) Scintigraphic detection of TNF in patients with rheumatoid arthritis. Ann.Rheum.Dis. 62, 825 828.
- Bendtzen K, Hansen MB, Ross C, Poulsen LK, Svenson M. Cytokines and autoantibodies to cytokines. Stem Cells. 1995 May- 13(3): 206−22.
- Blease K., Jakubzick C., Westwick J. Lukacs N., Kunkel S.L. Hogaboam C.M. (2001) Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma. J. Immunol. 166, 5219−5224.
- Boehm U., Klamp T., Groot M. Howard J.C. (1997) Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15, 749−795.
- Borish L., Nelson H., Corren J., Bensch G., Busse W.W., Whitmore J.B. Agosti J.M. (2001) Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. Allergy Clin. Immunol. 107, 963−970.
- Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garrison L. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med. 1999 Dec- 160(6): 1816−23.
- Bradley LM, Dalton DK, Croft M. A direct role for IFN-gamma in regulation of Thl cell development. J Immunol. 1996 Aug 15- 157(4): 1350−8.
- Brinkmann V, Geiger T, Alkan S, Heusser CH. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med. 1993 Nov 1- 178(5): 1655−63.
- Caruso A, Foresti I, Gribaudo G, Bonfanti C, Pollara P, Dolei A, Landolfo S, Turano A. Anti-interferon-gamma antibodies in sera from HIV infected patients. J Biol Regul Homeost Agents. 1989 Jan-Mar- 3(1):8−12.
- Cher DJ, Mosmann TR. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J Immunol. 1987 Jun 1- 138(11): 3688−94.
- Cohn L, Whittaker L, Niu N, Homer RJ. Cytokine regulation of mucus production in a model of allergic asthma. Novartis Found Symp. 2002- 248: 20 113
- Constant SL, Bottomly K. Induction of Thl and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol. 1997- 15: 297−322.
- Cote-Sierra J, Foucras G, Guo L, Chiodetti L, Young HA, Hu-Li J, Zhu J, Paul WE. Interleukin 2 plays a central role in Th2 differentiation. Proc Natl Acad Sci USA. 2004 Mar 16- 101(11): 3880−5.
- Cunningham A.J. (1965) A method of increased sensitivity for detecting single antibody-producing cells. Nature 207, 1106−1107.
- Davidson N.J. The therapeutic potential of anti-cytokine antibodies in the treatment of chronic inflammatory disease. Expert Opin. Investig. Drugs. 1998. Vol.7 P. l 115−1120.
- De Maeyer-Guignard J, Cachard-Thomas A, De Maeyer E. Naturally occurring anti-interferon antibodies in Lou/c rats. J Immunol. 1984 Aug- 133(2): 775−8.
- De Maeyer-Guignard J, De Maeyer E. Natural antibodies to interferon-alpha and interferon-beta are a common feature of inbred mouse strains. J Immunol. 1986 Marl- 136(5): 1708−11.
- Dinarello C.A. (1992) Anti-cytokine strategies. Eur Cytokine Netw. 3, 7−17.
- Erb KJ. Helminths, allergic disorders and IgE-mediated immune responses: where do we stand? Eur J Immunol. 2007 May- 37(5): 1170−3.
- Fahy JV, Corry DB, Boushey HA. Airway inflammation and remodeling in asthma. Curr Opin Pulm Med. 2000 Jan- 6(1): 15−20.
- Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003 Jan 15- 167(2): 199−204.
- Fox D.A., Choilazzi N. and Katz D.H. (1976) Hapten-specific IgE antibody response in mice. Differential resistance of IgE and IgG B-lymphocytes to X-radiation. J.Immunol. 117,1622−1628.
- Fulcher D.A., Wong S. Carboxifluorescein succinyl ester-based proliferative assays for assessment of T cell function in the diagnostic laboratory. Immunology and Cell biology. 1999. V. 77. P. 559−564.
- Genberg H., Hansson A., Wernerson A., Wennberg L. and Tyden G. (2006) Pharmacodynamics of rituximab in kidney transplantation. Am.J.Transplant. 6, 2418−2428.
- Graber P, Gretener D, Herren S. et al. The distribution of IL-13 receptor alphal expression on B cells, T cells and monocytes and its regulation by IL-13 and IL-4. Eur J Immunol. 1998 Dec- 28(12):4286−98.
- Grakoui A, Donermeyer DL, Kanagawa O, Murphy KM, Allen PM. TCR-independent pathways mediate the effects of antigen dose and altered peptide ligands on Th cell polarization. J Immunol. 1999 Feb 15- 162(4): 1923−30.
- Green JM, Noel PJ, Sperling AI, Walunas TL, Gray GS, Bluestone JA, Thompson CB. Absence of B7-dependent responses in CD28-deficient mice. Immunity. 1994 Sep-l (6):501−8.
- Groux H, Sornasse T, Cottrez F, de Vries JE, Coffman RL, Roncarolo MG, Yssel H. Induction of human T helper cell type 1 differentiation results in loss of IFN-gamma receptor beta-chain expression. J Immunol. 1997 Jun 15- 158(12):5627−31.
- Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature. 2000 Mar 23- 404(6776) :407-ll.
- Hansen MB, Svenson M, Diamant M, Abell K, Bendtzen K. Interleukin-6 autoantibodies: possible biological and clinical significance. Leukemia. 1995 Jul- 9(7):1113−5.
- Holgate S.T. Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Cytokine. 2004.- Vol.28.- P. 152−157.
- Hopp T.P., Woods K.R. A computer program for predicting protein antigenic determinants. Mol.Immunol. 1983. Vol.20. P.483−489.
- Hosken NA, Shibuya K, Heath AW, Murphy KM, O’Garra A. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J Exp Med. 1995 Nov 1- 182(5): 1579−84.
- Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993 Apr 23- 260(5107):547−9.
- Heusser CH, Bews J, Brinkmann V, Delespesse G, Kilchherr E, Ledermann F, Le Gros G, Wagner K. New concepts of IgE regulation. Int Arch Allergy Appl Immunol. 1991- 94(1−4):87−90.
- Ichinose M, Barnes PJ. Curr Cytokine-regulated accumulation of eosinophnjis in inflammatory disease. Drug Targets Inflamm Allergy. 2004 Sep- 3(3):263−9.
- Ichinose M, Barnes PJ. Cytokine-directed therapy in asthma. Curr Drug Targets Inflamm Allergy. 2004 Sep- 3(3): 263−9.
- Jacob CO, Holoshitz J, Van der Meide P, Strober S, McDevitt HO. Heterogeneous effects of IFN-gamma in adjuvant arthritis. J Immunol. 1989 Mar 1- 142(5): 1500−5.
- Jung T., Schauer U. Heusser C, Neumann C, Rieger C. Detection of intercellular cytokines by flow cytometry. J.Immunol. Meth. 1993. Vol. 159. P. 197−207.
- Jyonouchi H., Sun S., Winship T., Kuchan M. J. Dietary ribonucleotides modulate type 1 and type 2 T-helper cell responses against ovalbumin in young BALB/cJ mice. J. Nutr. 2001 Vol. 131. P. 1165−1170.
- Kidd P. Thl/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev. 2003 Aug- 8(3): 223−46.
- Kips JC, O’Connor BJ, Langley SJ. et al. Effect of SCH55700, a humanized antihuman interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003 Jun 15- 167(12): 1655−9.
- Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vmicek J, Daddona P, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993 Nov- 30(16):1443−53.
- Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Kohler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature. 1993 Mar 18- 362(6417): 245−8.
- Leckie MJ, ten Brincke A, Khan J. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000 Dec 23−30- 356(9248):2144−8.
- Mac Donald S. M., Lichtenstein L. M. Histamine releasing factots and heterogeneity of IgE. Springer Sem. Immunopathol. 1990, v. 12, p. 415−428.
- Maini R.N., Taylor P.C. (2000) Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med. 51,207−229.
- Magram J, Sfarra J, Connaughton S, Faherty D, Warrier R, Carvajal D, Wu CY, Stewart C, Sarmiento U, Gately MK. IL-12-deficient mice are defective but not devoid of type 1 cytokine responses. Ann N Y Acad Sci. 1996a Oct 31- 795: 6070.
- Magram J, Connaughton SE, Warrier RR, Carvajal DM, Wu CY, Ferrante J, Stewart C, Sarmiento U, Faherty DA, Gately MK. IL-12-deficient mice are defective in IFN- gamma production and type 1 cytokine responses. Immunity. 1996b May- 4(5):471−81.
- Moll H, Rollinghoff M. Resistance to murine cutaneous leishmaniasis is mediated by TH1 cells, but disease-promoting CD4+ cells are different from TH2 cells. Eur J Immunol. 1990 Sep- 20(9):2067−74.
- Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol. 2000 Sep- 1(3): 199−205.
- Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profejies of lymphokine activities and secreted proteins. J Immunol. 1986 Apr 1- 136(7):2348−57.
- Mosmann TR, Sad S. The expanding universe of T-cell subsets: Thl, Th2 and more. Immunol Today. 1996 Mar- 17(3): 138−46.
- Muraille E, Leo O. Revisiting the Thl/Th2 paradigm. Scand J Immunol. 1998 Jan- 47(1): 1−9.
- Nakamura T, Lee RK, Nam SY, Podack ER, Bottomly K, Flavell RA. Roles of IL-4 and IFN-gamma in stabilizing the T helper cell type 1 and 2 phenotype. J Immunol. 1997 Mar 15- 158(6): 2648−53.
- Noben-Trauth N, Kropf P, Muller I. SusceptibHJiity to Leishmania major infection in interleukin-4-deficient mice. Science. 1996 Feb 16- 271(5251):987−90.
- O’Byrne PM. Cytokines or their antagonists for the treatment of asthma. Chest. 2006 Jul- 130(l):244−50.
- Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunol Res. 2006- 34(2):97-l 15.
- Oppmann B, Lesley R, Blom B et al. Novel pl9 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000 Nov- 13(5):715−25.
- Parham C, Chirica M, Timans J et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbetal and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002 Jun 1- 168(11):5699−708.
- Perez VL, Lederer JA, Lichtman AH, Abbas AK. Stability of Thl and Th2 populations. Int Immunol. 1995 May- 7(5): 869−75.
- Pflanz S, Timans JC, Cheung J. et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity. 2002 Jun- 16(6):779−90.
- Presky DH, Yang H, Minetti LJ, Chiia AO, Nabavi N, Wu CY, Gately MK, Gubler U. A functional interleukin 12 receptor complex is composed of two betatype cytokine receptor subunits. Proc Natl Acad Sei USA. 1996 Nov 26- 93(24):14 002−7.
- Pullerits T. Cytokine modulation for anti-allergic treatment. Curr Pharm Des. 2002- 8(20): 1845−53.
- Purkerson J, Isakson P. A two-signal model for regulation of immunoglobulin isotype switching. FASEB J. 1992 Nov- 6(14):3245−52.
- Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn’s disease, sepsis, and myelodysplastic syndromes. Microsc. Res. Tech. 2000.- Vol. 50.- P.229−235.
- Revoltella RP, Laricchia-Robbio L, Moscato S, Genua A, Liberati AM. Natural and therapy-induced anti-GM-CSF and anti-G-CSF antibodies in human serum. Leuk Lymphoma. 1997 Dec- 26 Suppl 1:29−34.
- Revoltella RP. Natural and therapeutically-induced antibodies to cytokines. Biotherapy. 1998- 10(4):321−31.
- Rincon M, Anguita J, Nakamura T, Fikrig E, Flavell RA. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med. 1997 Feb 3- 185(3):461−9.
- Rogge L, Barberis-Maino L, Biffi M, Passini N, Presky DH, Gubler U, Sinigaglia F. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med. 1997 Mar 3- 185(5):825−31.
- Rogge L, D’Ambrosio D, Biffi M, Penna G, Minetti LJ, Presky DH, Adorini L, Sinigaglia F. The role of Stat4 in species-specific regulation of Th cell development by type I IFN-s. J Immunol. 1998 Dec 15- 161(12):6567−74.
- Romagnani S. Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol. 1992- 98(4):279−85.
- Romagnani S. The Thl/Th2 paradigm. Immunol Today. 1997 Jun- 18(6):263−266.
- Romagnani S. Thl and Th2 in human diseases. Clin Immunol Immunopathol. 1996 Sep- 80(3 Pt l):225−35.
- Ross C, Hansen MB, Schyberg T, Berg K. Autoantibodies to crude human leucocyte interferon (IFN-), native human IFN-, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Clin Exp Immunol. 1990 Oct- 82(l):57−62.
- Rost B. PHD: predicting one-dimensional protein structure by profile based neural networks. Meth. in Enzymolgy, 266, 525−539, 1996
- Ryan JJ, Kashyap M, Bailey D, Kennedy S, Speiran K, Brenzovich J, Barnstein B, Oskeritzian C, Gomez G. Mast cell homeostasis: a fundamental aspect of allergic disease. Crit Rev Immunol. 2007- 27(l):15−32.
- Schijns VE, Haagmans BL, Wierda CM, Kruithof B, Heijnen IA, Alber G, Horzinek MC. Mice lacking IL-12 develop polarized Thl cells during viral infection. J Immunol. 1998 Apr 15- 160(8):3958−64.
- Schweitzer AN, Borriello F, Wong RC, Abbas AK, Sharpe AH. Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86. J Immunol. 1997 Mar 15- 158(6):2713−22.
- Scott P. IFN-gamma modulates the early development of Thl and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol. 1991 Nov 1- 147(9): 3149−55.
- Shiohara M, Koike K. Regulation of mast cell development. Chem Immunol Allergy. 2005- 87: 1−21.
- Simon HU. Cytokine and anti-cytokine therapy for asthma. Curr Allergy Asthma Rep. 2006 Mar- 6(2): 117−21.
- Sitkauskiene B, Radinger M, Bossios A, Johansson AK, Sakalauskas R, Lotvall J. Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9. Respir Res. 2005 Apr 11- 6: 33.
- Steinhoff U, Muller U, Schertler A, Hengartner H, Aguet M, Zinkernagel RM. Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice. J Virol. 1995 Apr- 69(4): 2153−8.
- Steinke JW. Anti-interleukin-4 therapy. Immunol Allergy Clin North Am. 2004 Nov- 24(4): 599−614.
- Steinke JW., Vexler V., Lane N. et al. The safety and pharmacokinetics of SB240683 in patients with mild to moderate asthma. J. Allergy Clin. Immunol. 2001- 107: S317.
- Sumi Y, Hamid Q. Airway remodeling in asthma. Allergol Int. 2007 Dec- 56(4): 341−8.
- Svenson M, Hansen MB, Ross C, Diamant M, Rieneck K, Nielsen H, Bendtzen K. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood. 1998 Mar 15- 91(6): 2054−61.
- Szabo SJ, Dighe AS, Gubler U, Murphy KM. Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Thl) and Th2 cells. J Exp Med. 1997 Mar3- 185(5):817−24.
- Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Thl immune responses. Annu Rev Immunol. 2003- 21: 713−58.
- Van der Meide PH, Schellekens H. Anti-cytokine autoantibodies: epiphenomenon or critical modulators of cytokine action. Biotherapy. 1997- 10(1): 39−48.
- Vermeer PD, Harson R, Einwalter LA, Moninger T, Zabner J. Interleukin-9 induces goblet cell hyperplasia during repair of human airway epithelia. Am J Respir Cell Mol Biol. 2003 Mar- 28(3): 286−95.
- Walsh GM. Targeting airway inflammation: novel therapies for the treatment of asthma. Curr Med Chem. 2006- 13(25): 3105−11.
- Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol. 1993 Feb- 20(2): 25 962.
- Wenner CA, Guler ML, Macatonia SE, O’Garra A, Murphy KM. Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J Immunol. 1996 Feb 15- 156(4): 1442−7.
- Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev. 2004 Dec- 202: 175−90.
- Wu C, Ferrante J, Gately MK, Magram J. Characterization of IL-12 receptor betal chain (IL-12Rbetal)-deficient mice: IL-12Rbetal is an essential component of the functional mouse IL-12 receptor. J Immunol. 1997 Aug 15- 159(4): 165 865.
- Wu C, Wang X, Gadina M, O’Shea JJ, Presky DH, Magram J. IL-12 receptor beta 2 (IL-12R beta 2)-deficient mice are defective in IL-12-mediated signaling despite the presence of high affinity IL-12 binding sites. J Immunol. 2000 Dec 1- 165(11): 6221−8.
- Yamagata T, Ichinose M. Agents against cytokine synthesis or receptors. Eur J Pharmacol. 2006 Mar 8- 533(1−3):289−301.
- Yoshinaga SK, Whoriskey JS, Khare SD, et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature. 1999 Dec 16- 402(6763): 827−32.
- Zuany-Amorim C, Manlius C, Dalum I, Jensen MR, Gautam A, Pay G, Mouritsen S, Walker C. Induction of TNF-alpha autoantibody production by
- Auto Vac TNF106: a novel therapeutic approach for the treatment of allergic diseases. Int Arch Allergy Immunol. 2004 Feb- 133(2): 154−63.О1. Благодарности /